# A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-039

> **NCT03502954** · PHASE1 · TERMINATED · sponsor: **Affibody** · enrollment: 66 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** ABY-039
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03502954
- **Lead sponsor:** Affibody
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-26
- **Primary completion:** 2020-02-01
- **Final completion:** 2020-03-20
- **Target enrollment:** 66 (ACTUAL)
- **Why stopped:** Halted prematurely
- **Last updated:** 2020-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03502954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03502954, "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-039". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03502954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*